Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 14/20 | 0.50 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30263682 | 1.00 | SLC5A2 (0.50) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL3683414 | 0.89 | SLC5A2 (0.51) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL15397883 | 0.85 | HTR2A (0.42) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL29386304 | 0.84 | SLC5A2 (0.53) | SLC5A2SLC5A1ALDH1A1GAAMAPT | |
| SCHEMBL38150 | 0.84 | SLC5A2 (0.53) | SLC5A2SLC5A1ALDH1A1GAAMAPT | |
| SCHEMBL30017880 | 0.83 | HTR2A (0.40) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL29442727 | 0.83 | DHODH (0.44) | HTR2ASLC6A4KCNH2MEN1KMT2A | |
| SCHEMBL18322528 | 0.83 | DHODH (0.44) | HTR2ASLC6A4KCNH2MEN1KMT2A | |
| SCHEMBL24593196 | 0.83 | HTR2A (0.43) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL19303580 | 0.83 | HTR2A (0.43) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114288972-B | Reaction equipment for dapagliflozin intermediate and preparation method thereof | 浙江拓普药业股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-115073271-A | Preparation method of 4' - (5-bromo-2-chlorobenzyl) phenol | 苏州敬业医药化工有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-118063294-A | Efficient preparation method of dapagliflozin intermediate | 山东新时代药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3634970-B1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LTD (IN) | 2023-07-19 | — | — | EP | disclosed |
| CN-115716821-A | Method for continuously producing englezin by using microchannel reactor | 恒升德康(南京)医药科技有限公司 | 2023-02-28 | — | — | CN | disclosed |
| WO-2023005587-A1 | SYNTHESIS METHOD FOR EMPAGLIFLOZIN KEY INTERMEDIATE | 山东铂源药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| CN-115073271-A | Preparation method of 4' - (5-bromo-2-chlorobenzyl) phenol | 苏州敬业医药化工有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114288972-A | Reaction equipment for dapagliflozin intermediate and preparation method thereof | 浙江拓普药业股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-20060009400-A1 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-12 | — | — | US | disclosed |
| WO-2005092877-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
| US-6936590-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1224195-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | US | disclosed |
| EP-1224195-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6414126-B1 | ANTIDIABETIC, ANTIOBESITY, ANTILIPEMIC, ANTIATHEROSCLEROTIC, ANTICOAGULANT, AND HYPOTENSIVE AGENTS; MARKUSH ENCOMPASSING DAPAGLIFOZIN AND DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885HTR2A 1688/4885 |
| US-20050209166-A1 | Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885HTR2A 2064/4885 |
| US-20060009400-A1 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885HTR2A 1459/4885 |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885HTR2A 2462/4885 |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885HTR2A 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.